Stocks Health care HAE
NYSE · Health careHaemonetics Corp (HAE)
Haemonetics Corp brought in $1.4B of revenue over the twelve months to September 26, 2026, up 4.1% from a year earlier. Net income was $103.9M, a net margin of 7.5%. Operating cash flow minus capital spending left $260.4M of free cash flow in fiscal 2026. At September 26, 2026 it held $260.7M in cash against $1.1B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Haemonetics Corp
- Net worth
- Haemonetics Corp has a market value (market cap) of $5.6B at the latest share price, and shareholders' equity of $898.5M on its balance sheet at September 26, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2026 revenue was $1.3B (-2.0% year on year), with net income of $97.3M. Over the 12 months to September 26, 2026: revenue $1.4B, net income $103.9M.
- Cash flow
- In fiscal 2026 operations brought in $293.2M of cash; after $32.8M of capital spending, free cash flow was $260.4M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 26, 2026. Open on SEC EDGAR
- Next earnings report
- Haemonetics Corp's next report is expected around February 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Haemonetics Corp does
Haemonetics Corp is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NYSE under the ticker HAE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | $1.3B | $97.3M | $2.05 | $260.4M |
| 2025 | $1.4B | $167.7M | $3.31 | $142.4M |
| 2024 | $1.3B | $117.6M | $2.29 | $143.6M |
| 2023 | $1.2B | $115.4M | $2.24 | $81.7M |
| 2022 | $993.2M | $43.4M | $0.84 | $75.8M |
| 2021 | $870.5M | $79.5M | $1.55 | $71.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where HAE ranks in Health care
Latest SEC filings
What Haemonetics Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 26, 2026Revenue rose 9.3% to $357.8M versus the same quarter last year; diluted EPS $1.00 versus $0.81.
- November 5, 2026
- October 8, 2026
- August 18, 2026
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026
- August 6, 2026Quarterly report 10-Q · period to June 27, 2026Revenue rose 5.6% to $339.4M versus the same quarter last year; diluted EPS $0.72 versus $0.70.
- August 6, 2026
- July 28, 2026
- June 9, 2026
What is HAE worth? A DCF from its reported cash flow
Insider trades
What the people running Haemonetics Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 30, 2026 | Galvin RoyEVP, Chief Commercial Officer | Shares withheld for tax | 146 | $17.5K |
| July 24, 2026 | Abernathy Robert EDirector | Received as pay | 2,538 | - |
| July 24, 2026 | Bryant Diane MDirector | Received as pay | 2,538 | - |
| July 24, 2026 | Coyle Michael JDirector | Received as pay | 2,538 | - |
| July 24, 2026 | Johnson Lloyd EmersonDirector | Received as pay | 2,538 | - |
| July 24, 2026 | Kroll Mark WDirector | Received as pay | 2,538 | - |
| July 24, 2026 | Pomeroy ClaireDirector | Received as pay | 2,538 | - |
| July 24, 2026 | Zane Ellen MDirector | Received as pay | 2,538 | - |
Who owns HAE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Portfolio Management13G, passive | 5.59% | April 29, 2026 |
| Vanguard Capital Management13G, passive | 5.26% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 329 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 5,909,258 | +289,279 |
| Neuberger Berman Group LLC | 4,179,443 | +618,525 |
| Vanguard Portfolio Management LLC | 2,546,394 | -12,922 |
| Aqr Capital Management LLC | 2,266,489 | -1,090,054 |
| Ariel Investments, LLC | 2,060,966 | new |
| Vanguard Capital Management LLC | 2,059,578 | -30,811 |
| State Street Corp | 1,818,186 | +45,288 |
| Dimensional Fund Advisors LP | 1,585,222 | +259,165 |
| Citadel Advisors LLC | 1,510,120 | +1,251,967 |
| Geode Capital Management, LLC | 1,287,240 | +68,262 |
| River Road Asset Management, LLC | 1,285,602 | -42,387 |
| Arrowstreet Capital, Limited Partnership | 1,155,351 | -227,653 |
| Goldman Sachs Group Inc | 1,046,019 | +93,199 |
| UBS Group AG | 983,378 | +456,761 |
| Fort Washington Investment Advisors Inc | 830,925 | -10,092 |
| Royal Bank of Canada | 780,248 | -77,717 |
| Allspring Global Investments Holdings, LLC | 765,120 | -125,104 |
| Deutsche Bank AG\ | 631,663 | +272,781 |
| Northern Trust Corp | 631,542 | +52,236 |
| Charles Schwab Investment Management Inc | 591,423 | +19,323 |
Insiders
15 insiders reported holding 829,687 shares in total, about $101.5M at the last price.
| Holder | Shares |
|---|---|
| Simon, ChristopherPresident & CEO, Director | 444,704 |
| Basil Michelle LEVP and General Counsel | 68,829 |
| DArecca JamesEVP, Chief Financial Officer | 54,444 |
| Miller Laurie A.SVP, Human Resources | 40,987 |
| Galvin RoyEVP, Chief Commercial Officer | 39,805 |
| Chan FrankEVP, Chief Operating Officer | 32,936 |
| Abernathy Robert EDirector | 27,519 |
| Kroll Mark WDirector | 27,295 |
| Zane Ellen MDirector | 21,911 |
| Pomeroy ClaireDirector | 19,410 |
Questions about HAE
What does Haemonetics Corp do?
Haemonetics Corp is a company in the Health care sector, listed on NYSE as HAE. Its shares trade on NYSE under the ticker HAE.
What is Haemonetics Corp's net worth?
Haemonetics Corp has a market value (market cap) of $5.6B at the latest share price, and shareholders' equity of $898.5M on its balance sheet at September 26, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Haemonetics Corp profitable?
Yes. Over the twelve months to September 26, 2026 it reported net income of $103.9M on revenue of $1.4B, a net margin of 7.5%.
How much revenue does Haemonetics Corp make?
Over the twelve months to September 26, 2026 Haemonetics Corp reported revenue of $1.4B. That is 4.1% more than a year earlier.
When did Haemonetics Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 26, 2026.
When is Haemonetics Corp's next earnings report?
Haemonetics Corp's next report is expected around February 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare HAE with
Follow HAE
Get an email when Haemonetics Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Haemonetics Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.